Chengdu huasun technology group Inc. , LTD.

SZSE:000790 Stock Report

Market Cap: CN¥2.6b

Chengdu huasun technology group Valuation

Is 000790 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000790 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000790 (CN¥4.21) is trading above our estimate of fair value (CN¥0.21)

Significantly Below Fair Value: 000790 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000790?

Key metric: As 000790 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 000790. This is calculated by dividing 000790's market cap by their current revenue.
What is 000790's PS Ratio?
PS Ratio2.6x
SalesCN¥994.00m
Market CapCN¥2.63b

Price to Sales Ratio vs Peers

How does 000790's PS Ratio compare to its peers?

The above table shows the PS ratio for 000790 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4x
603811 Zhejiang Cheng Yi Pharmaceutical
3.5xn/aCN¥2.5b
301331 Enwei Pharmaceutical
3.1xn/aCN¥2.4b
001367 Zhejiang Haisen Pharmaceutical
6.4xn/aCN¥2.8b
002864 Shaanxi Panlong Pharmaceutical Group Limited By Share
2.9xn/aCN¥2.8b
000790 Chengdu huasun technology group
2.6xn/aCN¥2.6b

Price-To-Sales vs Peers: 000790 is good value based on its Price-To-Sales Ratio (2.6x) compared to the peer average (4x).

Price to Sales Ratio vs Industry

How does 000790's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
600664 Harbin Pharmaceutical Group
0.6xn/aUS$1.28b
000411 Zhejiang Int'l GroupLtd
0.2xn/aUS$758.85m
000153 Anhui Fengyuan Pharmaceutical
0.7xn/aUS$399.69m
600781 FUREN Group PharmaceuticalLtd
0.3xn/aUS$66.91m
000790 2.6xIndustry Avg. 3.5xNo. of Companies36PS02.85.68.411.214+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 000790 is good value based on its Price-To-Sales Ratio (2.6x) compared to the CN Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 000790's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000790 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.6x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 000790's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%